ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/omet2016332-36ometendo-8206Research ArticleОбзор литературыReviewЛечение сахарного диабета 2 типа: устойчивость сахароснижающего действия препаратовTreatment of type 2 diabetes: the stability of the effectiveness of hypoglycemic medicationsМоргуноваТатьяна БорисовнаMorgunovaTat'yanatanmorgun@mail.ruФадеевВалентин ВикторовичFadeevValentintanmorgun@mail.ruГБOУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России, МоскваРоссияI.M. Sechenov’s First Moscow State Medical University, Moscow, RussiaRussian Federation2016091120161333236Copyright © Моргунова Т.Б., Фадеев В.В., 20162016Моргунова Т.Б., Фадеев В.В.Morgunova T., Fadeev V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/8206сахарный диабетлечениеингибиторы дипептидилпептидазы-4устойчивость сахароснижающего действияdiabetes mellitustreatmentDPP-4 inhibitorsglycemic durabilityReferencesGodinho R, Mega C, Teixeira-de-Lemos E, et al. The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class? Journal of Diabetes Research. 2015;2015:1-28. doi: 10.1155/2015/806979.Godinho R, Mega C, Teixeira-de-Lemos E, et al. The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class? Journal of Diabetes Research. 2015;2015:1-28. doi: 10.1155/2015/806979.Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014;38(1):140-149. doi: 10.2337/dc14-2441.Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2014;38(1):140-149. doi: 10.2337/dc14-2441.Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm –2016 Executive Summary. Endocr Pract. 2016;22(1):84-113. doi: 10.4158/ep151126.cs.Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm –2016 Executive Summary. Endocr Pract. 2016;22(1):84-113. doi: 10.4158/ep151126.cs.American Diabetes Association. Approaches to Glycemic Treatment. Diabetes Care. 2014;38(Supplement_1):S41-S48. doi: 10.2337/dc15-S010.American Diabetes Association. Approaches to Glycemic Treatment. Diabetes Care. 2014;38(Supplement_1):S41-S48. doi: 10.2337/dc15-S010.International Diabetes Federation Guideline Development Group. Global Guideline for Type 2 Diabetes. Diabetes Res Clin Pract. 2014;104(1):1-52. doi: 10.1016/j.diabres.2012.10.001.International Diabetes Federation Guideline Development Group. Global Guideline for Type 2 Diabetes. Diabetes Res Clin Pract. 2014;104(1):1-52. doi: 10.1016/j.diabres.2012.10.001.Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск). // Сахарный диабет. – 2015. – Т. 18. – №1S – C. 1-112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). Diabetes mellitus. 2015;18(1S):1-112. (In Russ.)] doi: 10.14341/DM20151S1-112Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск). // Сахарный диабет. – 2015. – Т. 18. – №1S – C. 1-112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V. (7th edition). Diabetes mellitus. 2015;18(1S):1-112. (In Russ.)] doi: 10.14341/DM20151S1-112Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016;6(1):e010210. doi: 10.1136/bmjopen-2015-010210.Sharma M, Nazareth I, Petersen I. Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open. 2016;6(1):e010210. doi: 10.1136/bmjopen-2015-010210.Thomsen RW, Baggesen LM, Søgaard M, et al. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes. Diabetologia. 2015;58(10):2247-2253. doi: 10.1007/s00125-015-3698-1.Thomsen RW, Baggesen LM, Søgaard M, et al. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes. Diabetologia. 2015;58(10):2247-2253. doi: 10.1007/s00125-015-3698-1.Kahn SE, Haffner SM, Heise MA, et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. N Engl J Med. 2006;355(23):2427-2443. doi: 10.1056/NEJMoa066224.Kahn SE, Haffner SM, Heise MA, et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. N Engl J Med. 2006;355(23):2427-2443. doi: 10.1056/NEJMoa066224.Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2015;109(2):378-388. doi: 10.1016/j.diabres.2015.05.025.Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2015;109(2):378-388. doi: 10.1016/j.diabres.2015.05.025.Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010;64(5):562-576. doi: 10.1111/j.1742-1241.2010.02353.x.Seck T, Nauck M, Sheng D, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 2010;64(5):562-576. doi: 10.1111/j.1742-1241.2010.02353.x.Göke B, Gallwitz B, Eriksson JG, et al. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract. 2013;67(4):307-316. doi: 10.1111/ijcp.12119.Göke B, Gallwitz B, Eriksson JG, et al. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract. 2013;67(4):307-316. doi: 10.1111/ijcp.12119.Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. The Lancet. 2012;380(9840):475-483. doi: 10.1016/s0140-6736(12)60691-6.Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. The Lancet. 2012;380(9840):475-483. doi: 10.1016/s0140-6736(12)60691-6.Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780-789. doi: 10.1111/j.1463-1326.2010.01233.x.Matthews DR, Dejager S, Ahren B, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780-789. doi: 10.1111/j.1463-1326.2010.01233.x.Feng J, Zhang Z, Wallace MB, et al. Discovery of Alogliptin: A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV†. J Med Chem. 2007;50(10):2297-2300. doi: 10.1021/jm070104l.Feng J, Zhang Z, Wallace MB, et al. Discovery of Alogliptin: A Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV†. J Med Chem. 2007;50(10):2297-2300. doi: 10.1021/jm070104l.Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008;30(3):513-527. doi: 10.1016/j.clinthera.2008.03.005.Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008;30(3):513-527. doi: 10.1016/j.clinthera.2008.03.005.Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16(12):1239-1246. doi: 10.1111/dom.12377.Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16(12):1239-1246. doi: 10.1111/dom.12377.Esposito K, Chiodini P, Maiorino MI, et al. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open. 2014;4(6):e005442-e005442. doi: 10.1136/bmjopen-2014-005442.Esposito K, Chiodini P, Maiorino MI, et al. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open. 2014;4(6):e005442-e005442. doi: 10.1136/bmjopen-2014-005442.Garber A, Henry RR, Ratner R, et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):348-356. doi: 10.1111/j.1463-1326.2010.01356.x.Garber A, Henry RR, Ratner R, et al. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):348-356. doi: 10.1111/j.1463-1326.2010.01356.x.Gallwitz B, Guzman J, Dotta F, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. The Lancet. 2012;379(9833):2270-2278. doi: 10.1016/s0140-6736(12)60479-6.Gallwitz B, Guzman J, Dotta F, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. The Lancet. 2012;379(9833):2270-2278. doi: 10.1016/s0140-6736(12)60479-6.Leiter LA, Yoon K-H, Arias P, et al. Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study. Diabetes Care. 2015;38(3):355-364. doi: 10.2337/dc13-2762.Leiter LA, Yoon K-H, Arias P, et al. Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study. Diabetes Care. 2015;38(3):355-364. doi: 10.2337/dc13-2762.Ridderstråle M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. The Lancet Diabetes & Endocrinology. 2014;2(9):691-700. doi: 10.1016/s2213-8587(14)70120-2.Ridderstråle M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. The Lancet Diabetes & Endocrinology. 2014;2(9):691-700. doi: 10.1016/s2213-8587(14)70120-2.Nauck MA, Del Prato S, Durán-García S, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014;16(11):1111-1120. doi: 10.1111/dom.12327.Nauck MA, Del Prato S, Durán-García S, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014;16(11):1111-1120. doi: 10.1111/dom.12327.Nathan DM, Buse JB, Kahn SE, et al. Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2013;36(8):2254-2261. doi: 10.2337/dc13-0356.Nathan DM, Buse JB, Kahn SE, et al. Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2013;36(8):2254-2261. doi: 10.2337/dc13-0356.
The authors declare that there are no conflicts of interest present.